Crosby, E. J., Nagata, H., Telli, M. L., Acharya, C. R., Wapnir, I., Zablotsky, K., … Lyerly, H. K. (2021). Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients. In CANCER RESEARCH (Vol. 81).

Crosby, Erika J., Hiroshi Nagata, Melinda L. Telli, Chaitanya R. Acharya, Irene Wapnir, Kaitlin Zablotsky, Erica Browning, et al. “Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients.” In CANCER RESEARCH, Vol. 81, 2021.

Crosby EJ, Nagata H, Telli ML, Acharya CR, Wapnir I, Zablotsky K, et al. Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients. In: CANCER RESEARCH. 2021.

Crosby, Erika J., et al. “Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients.” CANCER RESEARCH, vol. 81, no. 4, 2021.

Crosby EJ, Nagata H, Telli ML, Acharya CR, Wapnir I, Zablotsky K, Browning E, Hermiz R, Svenson L, Bannavong D, Malloy K, Canton DA, Twitty CG, Osada T, Lyerly HK. Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients. CANCER RESEARCH. 2021.